학술논문
Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice
이용수 0
- 영문명
- Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice
- 발행기관
- 대한방사선종양학회
- 저자명
- Budhi Singh Yadav Treshita Dey
- 간행물 정보
- 『대한방사선종양학회지』제41권 제4호, 237~247쪽, 전체 11쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 2023.12.31
4,120원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Purpose: The standard treatment of non-Hodgkin lymphoma (NHL) comprises combined modality treatment, radiotherapy (RT), and chemotherapy with rituximab which has significantly improved both disease-free survival (DFS) and overall survival (OS). However, there is no uniformity in radiation dose usage in these patients. In this retrospective study, we compared lower radiation dose with higher in patients with aggressive NHL.
Materials and Methods: From 2007 to 2017, treatment records of all high-grade NHL or diffuse large B-cell lymphoma and non-central nervous system NHL were included. We compared response rates, OS and DFS of patients who received ≤30 Gy RT to those with >30 Gy. Univariate and multivariate analyses were done to determine factors affecting prognosis, i.e., age, sex, stage, International Prognostic Index (IPI), adding rituximab, and radiation dose.
Results: A total of 184 NHL patients treated with combined modality or radiation alone having complete follow-up details were analyzed. At median follow-up of 66.8 months, 5-year OS was 72.8% in high-dose group versus 69.9% in low-dose group (p = 0.772) and 5-year DFS 64.7% versus 64.1% (p = 0.871). Patients having early-stage disease receiving low dose and those with advanced disease treated with >30 Gy had better OS and DFS though not statistically significant. Adding rituximab was associated with significantly better OS and DFS irrespective of radiation dose delivered. High IPI score and omitting rituximab were the only factors that significantly worsened both OS and DFS. Acute radiation toxicities were comparable in both groups (p = 0.82). Among late toxicities, no patient developed a second malignancy and 5% died due to cardiovascular complications (p = 0.595) though only two patients (1.1%) had received thoracic radiation.
Conclusion: The two groups had comparable response rates, acute toxicities, DFS and OS. This study suggests that RT dose reduction may be possible in high-grade NHL without compromising the DFS and OS.
목차
Introduction
Materials and Methods
Results
Discussion and Conclusion
Statement of Ethics
Conflict of Interest
Funding
Author Contributions
Data Availability Statement
References
해당간행물 수록 논문
- Proton beam therapy as a promising option for high-risk limited stage small cell lung cancer: revealing potential of future novel agents
- Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice
- A comparison of conventional and accelerated hypofractionated radiotherapy in definitive chemoradiation for locally advanced head and neck carcinoma: a retrospective cohort study
- A case of cetuximab-induced radiation recall skin dermatitis and review of the literature
- Dynamic contrast-enhanced magnetic resonance imaging parameter changes as an early biomarker of tumor responses following radiation therapy in patients with spinal metastases: a systematic review
- CyberKnife-based stereotactic radiosurgery or fractionated stereotactic radiotherapy in older patients with brain metastases from non-small cell lung cancer
- Different approaches to target volume definition and boost delivery in surgery de-escalation clinical trial in breast cancer patients with pathological complete response
- Target movement according to cervical lymph node level in head and neck cancer and its clinical significance
- Synchronous radiation-induced enterovesical and enterocervical fistulas in carcinoma of the uterine cervix
- Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 두경부암에서 면역회피 기전과 면역항암제 치료
- 식도암에서 근치적 절제술 후 방사선치료의 역할
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!